Imaging findings in cancer therapy-associated neurotoxicity

Seminars in Neurology

Volumn 32, Issue 4, 2012, Pages 476-486

  Arrillaga Romany, Isabel C ^a,b   Dietrich, Jorg ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

chemotherapy; leukoencephalopathy; magnetic resonance imaging (MRI); neurotoxicity; radiation

Indexed keywords

ARABINOSIDE; ASPARAGINASE; BEVACIZUMAB; CARBOPLATIN; CARMOFUR; CARMUSTINE; CISPLATIN; DOXORUBICIN; FLUDARABINE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; MISONIDAZOLE; RITUXIMAB; SORAFENIB; SUNITINIB; THALIDOMIDE; VANDETANIB; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; ATAXIA; BRAIN ATROPHY; BRAIN DISEASE; BRAIN ISCHEMIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DROWSINESS; DRUG MEGADOSE; DYSMETRIA; FATIGUE; FEVER; GAIT DISORDER; HUMAN; IRRITABILITY; LEUKOENCEPHALOPATHY; LYMPHOMA; NEUROIMAGING; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; NYSTAGMUS; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; RADIATION DOSE; RADIATION NECROSIS; SOMNOLENCE; SPINAL CORD DISEASE; VOMITING; WHITE MATTER INJURY;

ANIMALS; ANTINEOPLASTIC AGENTS; DIAGNOSTIC IMAGING; HUMANS; NEOPLASMS; NEUROTOXICITY SYNDROMES;

EID: 84872922125     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0032-1331817     Document Type: Article

References (54)

1. Cross N. E., Glantz M. J. Neurologic complications of radiation therapy. Neurol Clin: 2003; 21 1 249 277 (Pubitemid 36169351)
2. Soussain C., Ricard D., Fike J. R., Mazeron J. J., Psimaras D., Delattre J. Y. CNS complications of radiotherapy and chemotherapy. Lancet: 2009; 374 9701 1639 1651
3. Rinne M. L., Lee E. Q., Wen P. Y. Central nervous system complications of cancer therapy. J Support Oncol: 2012; 10 4 133 141
4. Pruzincová L., Steno J., Srbeck M., et al. MR imaging of late radiation therapy- and chemotherapy-induced injury: a pictorial essay. Eur Radiol: 2009; 19 11 2716 2727
5. Marks J. E., Baglan R. J., Prassad S. C., Blank W. F. Cerebral radionecrosis: incidence and risk in relation to dose, time, fractionation and volume. Int J Radiat Oncol Biol Phys: 1981; 7 2 243 252 (Pubitemid 11149307)
6. Rabin B. M., Meyer J. R., Berlin J. W., Marymount M. H., Palka P. S., Russell E. J. Radiation-induced changes in the central nervous system and head and neck. Radiographics: 1996; 16 5 1055 1072 (Pubitemid 126448470)
7. Galloway T. J., Indelicato D. J., Amdur R. J., Swanson E. L., Smith A. A., Marcus R. B. Jr. Second tumors in pediatric patients treated with radiotherapy to the central nervous system. Am J Clin Oncol: 2012; 35 3 279 283
8. Taylor A. J., Little M. P., Winter D. L., et al. Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study. J Clin Oncol: 2010; 28 36 5287 5293
9. Moretti R., Torre P., Antonello R. M., et al. Neuropsychological evaluation of late-onset post-radiotherapy encephalopathy: a comparison with vascular dementia. J Neurol Sci: 2005; 229-230 195 200 (Pubitemid 40341583)
10. Dietrich J., Monje M., Wefel J., Meyers C. Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist: 2008; 13 12 1285 1295
11. Douw L., Klein M., Fagel S. S., et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol: 2009; 8 9 810 818
12. Monje M. L., Mizumatsu S., Fike J. R., Palmer T. D. Irradiation induces neural precursor-cell dysfunction. Nat Med: 2002; 8 9 955 962 (Pubitemid 35033699)
13. Monje M., Dietrich J. Cognitive side effects of cancer therapy demonstrate a functional role for adult neurogenesis. Behav Brain Res: 2012; 227 2 376 379
14. Michele M. Cranial radiation therapy and damage to hippocampal neurogenesis. Dev Disabil Res Rev: 2008; 14 238 242
15. Dropcho E. JE. Central nervous system injury by therapeutic irradiation. Neurol Clin: 1991; 9 4 969 988
16. Perry A., Schmidt R. E. Cancer therapy-associated CNS neuropathology: an update and review of the literature. Acta Neuropathol: 2006; 111 3 197 212
17. Yoshii Y. Pathological review of late cerebral radionecrosis. Brain Tumor Pathol: 2008; 25 2 51 58
18. Morris P. G., Gutin P. H., Avila E. K., Rosenblum M. K., Lassman A. B. Seizures and radionecrosis from non-small-cell lung cancer presenting as increased fluorodeoxyglucose uptake on positron emission tomography. J Clin Oncol: 2011; 29 12 e324 e326
19. Wang Y. X., King A. D., Zhou H., et al. Evolution of radiation-induced brain injury: MR imaging-based study. Radiology: 2010; 254 1 210 218
20. Chan Y. L., Leung S. F., King A. D., Choi P. H., Metreweli C. Late radiation injury to the temporal lobes: morphologic evaluation at MR imaging. Radiology: 1999; 213 3 800 807
21. Brandes A. A., Franceschi E., Tosoni A., et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol: 2008; 26 13 2192 2197
22. Schiff D., Wen P. Y., van den Bent M. J. Neurological adverse effects caused by cytotoxic and targeted therapies. Nat Rev Clin Oncol: 2009; 6 10 596 603
23. Hustinx R., Pourdehnad M., Kaschten B., Alavi A. PET imaging for differentiating recurrent brain tumor from radiation necrosis. Radiol Clin North Am: 2005; 43 1 35 47 (Pubitemid 40326558)
24. Baker W. J., Royer G. L. Jr, Weiss R. B. Cytarabine and neurologic toxicity. J Clin Oncol: 1991; 9 4 679 693
25. Winkelman M. D., Hines J. D. Cerebellar degeneration caused by high-dose cytosine arabinoside: a clinicopathological study. Ann Neurol: 1983; 14 5 520 527 (Pubitemid 14239719)
26. Pirzada N. A., Ali I. I., Dafer R. M. Fluorouracil-induced neurotoxicity. Ann Pharmacother: 2000; 34 1 35 38 (Pubitemid 30058922)
27. Dietrich J., Wen P. Y. Neurologic complications of chemotherapy. In: Schiff D., Kesari S., Wen P. Y., eds. Cancer Neurology in Clinical Practice. Totowa, NJ Humana Press: 2008; 287 326
28. Filley C. M., Kleinschmidt-DeMasters B. K. Toxic leukoencephalopathy. N Engl J Med: 2001; 345 6 425 432 (Pubitemid 32750305)
29. Plotkin S. R., Wen P. Y. Neurologic complications of cancer therapy. Neurol Clin: 2003; 21 1 279 318, x x. (Pubitemid 36169352)
30. Raghavendra S., Nair M. D., Chemmanam T., et al. Disseminated necrotizing leukoencephalopathy following low-dose oral methotrexate. Eur J Neurol: 2007; 14 309 314 (Pubitemid 46384869)
31. Vazquez E., Lucaya J., Castellote A., et al. Neuroimaging in pediatric leukemia and lymphoma: differential diagnosis. Radiographics: 2002; 22 1411 1428
32. Ohmoto Y. Y., Kajiwara K. K., Kato S. S., Nisizaki T., Ito H., Tamura S. Atypical MRI findings in treatment-related leukoencephalopathy: case report. Neuroradiology: 1996; 38 2 128 133 (Pubitemid 26048204)
33. Oka M., Terae S., Kobayashi R., et al. MRI in methotrexate-related leukoencephalopathy: Disseminated necrotising leukoencephalopathy in comparison with mild leukoencephalopathy. Neuroradiology: 2003; 45 7 493 497 (Pubitemid 36944066)
34. Marinella M. A., Markert R. J. Reversible posterior leucoencephalopathy syndrome associated with anticancer drugs. Intern Med J: 2009; 39 12 826 834
35. Bartynski W. S., Boardman J. F. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol: 2007; 28 7 1320 1327 (Pubitemid 47309666)
36. Ryan S. A., Maceneaney P., O'Reilly S. P., Moylan E. J., Power D. G. Reversible posterior leukoencephalopathy induced by carboplatin and etoposide. Med Oncol: 2012; 29 2 1287 1291
37. Vaughn C., Zhang L., Schiff D. Reversible posterior leukoencephalopathy syndrome in cancer. Curr Oncol Rep: 2008; 10 1 86 91
38. Bartynski W. S. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol: 2008; 29 6 1043 1049 (Pubitemid 351954864)
39. Bartynski W. S. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol: 2008; 29 6 1036 1042 (Pubitemid 351954863)
40. Grisold W., Oberndorfer S., Struhal W. Stroke and cancer: a review. Acta Neurol Scand: 2009; 119 1 1 16
41. Choueiri T. K., Schutz F. A., Je Y., Rosenberg J. E., Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol: 2010; 28 13 2280 2285
42. Schutz F. A., Je Y., Azzi G. R., Nguyen P. L., Choueiri T. K. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol: 2011; 22 6 1404 1412
43. Yang J. C., Haworth L., Sherry R. M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med: 2003; 349 5 427 434 (Pubitemid 36910021)
44. Gordon M. S., Margolin K., Talpaz M., et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol: 2001; 19 3 843 850 (Pubitemid 32119100)
45. Johnson D. H., Fehrenbacher L., Novotny W. F., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol: 2004; 22 11 2184 2191 (Pubitemid 41095154)
46. Carden C. P., Larkin J. M., Rosenthal M. A. What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro-oncol: 2008; 10 4 624 630
47. Norden A. D., Drappatz J., Wen P. Y. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol: 2009; 5 11 610 620
48. Norden A. D., Bartolomeo J., Tanaka S., et al. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. J Neurooncol: 2012; 106 1 121 125
49. Kieslich M., Porto L., Lanfermann H., Jacobi G., Schwabe D., Böhles H. Cerebrovascular complications of L-asparaginase in the therapy of acute lymphoblastic leukemia. J Pediatr Hematol Oncol: 2003; 25 6 484 487 (Pubitemid 36682755)
50. Feinberg W. M., Swenson M. R. Cerebrovascular complications of L-asparaginase therapy. Neurology: 1988; 38 1 127 133 (Pubitemid 18028106)
51. Grace R. F., Dahlberg S. E., Neuberg D., et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol: 2011; 152 452 459
52. Giglio P., Gilbert M. R. Neurologic complications of cancer and its treatment. Curr Oncol Rep: 2010; 12 1 50 59
53. Watterson J., Toogood I., Nieder M., et al. Excessive spinal cord toxicity from intensive central nervous system-directed therapies. Cancer: 1994; 74 11 3034 3041 (Pubitemid 24361092)
54. Counsel P., Khangure M. Myelopathy due to intrathecal chemotherapy: magnetic resonance imaging findings. Clin Radiol: 2007; 62 2 172 176 (Pubitemid 46024207)